证券代码：300878 证券简称：维康药业 公告编号：2025-028 申请事项：境内生产药品注册上市许可 申请人：浙江维康药业股份有限公司 受理号：CYHS2502535 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。 二、维生素 K1滴剂的相关情况 浙江维康药业股份有限公司 关于获得维生素 K1滴剂上市申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日获得国家药品监督 管理局发出的维生素 K1 滴剂药品注册上市许可申请《受理通知书》。现将相关 情况公告如下： 一、受理通知书主要内容 产品名称：维生素 K1滴剂 截至本公告披露日，经查询国家药品监督管理局网站，取得该品种的药品批 准文号的企业有：广西铭磊维生制药有限公司。 四、对公司的影响及风险提示 根据国家相关法规规定，上述药品已获得注册申请受理，报送国家药监局药 品审评中心进行审评审批。上述药品获得受理通知书对公司近期业绩不会产生影 响，相关药品的注册批件取得时间和结果均具有不确定性。 公司将积极推进该项目进 ...

民生证券股份有限公司 关于浙江维康药业股份有限公司 关联方非经营性资金占用事项的专项现场检查报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为浙江 维康药业股份有限公司（以下简称"维康药业"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关法律、法规和规范性文件的规定和要求，对维 康药业关联方非经营性资金占用事项进行了专项现场检查，具体情况如下： 一、专项现场检查的基本情况 2024 年 4 月 18 日，公司及相关责任人员收到浙江证监局出具的《关于对刘 忠良、卢卫芳、孔晓霞、朱婷、王静采取出具警示函措施的决定》（〔2024〕49 号）、 《关于对浙江维康药业股份有限公司采取责令改正并出具警示函措施的决定》 （〔2024〕50 号）；2025 年 7 月 10 日，公司收到浙江证监局出具的《行政处罚决 定书》（〔2025〕16 号）。 根据浙江证监局查明的 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-027 浙江维康药业股份有限公司 关于公司及相关当事人收到中国证券监督管理委员 会浙江证监局《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）及公司实际控制人刘忠良 先生于 2024 年 12 月 27 日收到中国证券监督管理委员会（以下简称"中国证监 会"）下发的《中国证券监督管理委员会立案告知书》（编号：证监立案字 01120240040 号、编号：证监立案字 01120240041 号），因涉嫌信息披露违法违 规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规， 中国证监会决定对公司及公司实际控制人刘忠良先生立案。具体内容详见公司于 2024 年 12 月 30 日披露的《关于公司及实际控制人收到中国证券监督管理委员 会《立案告知书》的公告》（公告编号：2024-089）。 2025 年 6 月 27 日，公司收到中国证券监督管理委员会浙江监管局下发的《行 政处罚事先告知书》（浙处罚字[2025]9 号） ...

证券代码：300878 证券简称：维康药业 公告编号：2025-026 企业名称：浙江维康药业股份有限公司 注册地址：浙江省丽水经济开发区遂松路 2 号 浙江维康药业股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日取得浙江省药品监 督管理局换发的《药品生产许可证》，同意《药品生产许可证》变更申请。本次 变更主要涉及生产范围的新增。变更后的《药品生产许可证》具体内容如下： 一、《药品生产许可证》基本情况 社会信用代码：913311007047968289 法定代表人：刘洋 企业负责人：刘洋 质量负责人：纪晓燕 发证机关：浙江省药品监督管理局 有效期至：2025 年 12 月 31 日 许可证编码：浙 20000144 分类码：AhzyCh 生产地址和生产范围：浙江省丽水经济开发区遂松路 2 号：中药饮片〔含毒 性饮片、含直接口服饮片〕、丸剂（滴丸）、滴剂（胶囊型）（仅限注册申报使 用）、片剂、胶囊剂、软胶囊剂、颗粒剂*** 二、药品生产许可证副本变更情况 新增生产范 ...

Core Viewpoint - Zhejiang Weikang Pharmaceutical and its actual controller Liu Zhongliang have been implicated in significant financial misconduct, leading to a record penalty of 16 million yuan for information disclosure violations, highlighting the regulatory scrutiny in the pharmaceutical sector in Zhejiang [1][4]. Group 1: Financial Misconduct - Liu Zhongliang orchestrated a systematic violation of regulations by misappropriating over 150 million yuan from the company between 2020 and mid-2023, with the highest amount exceeding 10% of the company's net assets [2]. - The company failed to disclose these financial misappropriations in a timely manner, and during a bond issuance application in late 2022, it falsely claimed that no funds were occupied by the actual controller [2]. Group 2: Accountability and Penalties - Liu Zhongliang received a fine of 7 million yuan, with 5 million yuan attributed to his role as the actual controller and 2 million yuan for his direct responsibility in the violations [3]. - Several high-ranking executives, including the former general manager and financial director, were fined between 600,000 to 800,000 yuan for their failure to ensure the accuracy of financial reports and for signing off on misleading documents [3]. Group 3: Regulatory History - Weikang Pharmaceutical has a history of regulatory issues, including warnings for significant discrepancies in profit forecasts and inaccurate financial disclosures, indicating a pattern of non-compliance [4]. - The company has been under close regulatory scrutiny, with multiple warnings and penalties issued in recent years, reflecting a persistent issue with governance and financial integrity [4].

Core Viewpoint - Zhejiang Weikang Pharmaceutical Co., Ltd. is under investigation for information disclosure violations, leading to a total fine of 14.6 million yuan due to improper disclosure of related party non-operating fund occupation and inaccuracies in convertible bond prospectus [1][2][3] Group 1: Investigation and Penalties - The company and its actual controller, Liu Zhongliang, are being investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2] - The Zhejiang Securities Regulatory Bureau has issued a warning and imposed fines totaling 14.6 million yuan, including 5 million yuan for the company and 7 million yuan for Liu Zhongliang [3][4] - The penalties also include fines for other executives, with a total of 1.46 million yuan in fines for various responsible individuals [3] Group 2: Financial Misconduct - Liu Zhongliang allegedly organized the transfer of funds under the guise of paying for engineering equipment, which were ultimately diverted to his personal accounts, constituting non-operating fund occupation [2] - The occupied funds from 2020 to 2023 amounted to 142 million yuan, with the end-of-period balances being 78.12 million yuan, 89.51 million yuan, 147 million yuan, and 151 million yuan, respectively [2][6] - The company failed to disclose these fund occupations in its annual reports from 2020 to 2022 and the semi-annual report for 2023 [2] Group 3: Financial Performance - Weikang Pharmaceutical has experienced a decline in net profit since its listing, with losses starting in 2023, reporting net profits of 136 million yuan, 96.5 million yuan, 44.44 million yuan, -8.04 million yuan, and -147 million yuan from 2020 to 2024 [7] - The company attributed its declining performance to its products being removed from various provincial medical insurance directories, affecting sales [8] - In 2024, the company reported a significant impairment of fixed assets amounting to 87.42 million yuan due to underutilization of capacity and declining sales [8] Group 4: Future Strategies - The company plans to enhance sales of core products like Yinhuang滴丸 and expand sales channels while investing in research and development for innovative traditional Chinese medicine [9] - Weikang aims to strengthen its market position by focusing on the development of new products and exploring the health sector's potential [9]

Core Viewpoint - The company Weikang Pharmaceutical (300878.SZ) has been penalized 16 million yuan due to non-operational fund occupation by its actual controller and violations in information disclosure [2][3][6]. Group 1: Regulatory Actions and Penalties - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Weikang Pharmaceutical and its actual controller Liu Zhongliang for suspected violations of information disclosure [3]. - The CSRC found that from 2020 to 2023, Liu Zhongliang organized and directed the company to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal accounts, constituting non-operational fund occupation [3][5]. - The total penalties include 5 million yuan for Weikang Pharmaceutical, 7 million yuan for Liu Zhongliang, and 4 million yuan for five other executives, totaling 16 million yuan [6]. Group 2: Financial Performance and Issues - Weikang Pharmaceutical has experienced a decline in performance since its listing in August 2020, with consecutive losses in 2023 and 2024 [4][10]. - The net profits from 2021 to 2023 were 97 million yuan, 49 million yuan, and a loss of 9 million yuan, respectively [9]. - In 2024, the company reported a loss of 147 million yuan, with a particularly poor performance in the fourth quarter, where revenue was negative 20 million yuan [10][11]. Group 3: Operational Challenges - The company attributes its declining performance to several factors, including reduced demand for prescription drugs due to changes in medical insurance policies and market conditions, increased competition leading to lower gross margins, and a shift in product promotion strategies [10]. - In 2024, Weikang Pharmaceutical's sales expenses were 201 million yuan, accounting for 57.26% of its revenue, while R&D expenses were only 14 million yuan, representing 4% of revenue, a decrease of 66.85% year-on-year [10]. Group 4: Corporate Governance Changes - Due to the fund occupation issues, two executives left their positions, with Liu Zhongliang resigning as chairman and director in May 2024 [7].

Core Viewpoint - The investigation into Weikang Pharmaceutical (300878) revealed a four-year-long financial misconduct involving the misappropriation of funds by the actual controller, Liu Zhongliang, leading to significant penalties and ongoing operational challenges for the company [1][2]. Group 1: Financial Misconduct - Weikang Pharmaceutical received a penalty exceeding 14 million yuan due to undisclosed related-party fund misappropriation and false statements in convertible bond prospectuses [1]. - From 2020 to mid-2023, Liu Zhongliang transferred over 150 million yuan from the company to personal accounts under the guise of engineering equipment payments, with the highest annual misappropriation exceeding 10% of net assets [2]. - The scale of fund misappropriation increased from 78.11 million yuan in 2020 to 151 million yuan in 2023, with corresponding percentages of net assets being 5.64%, 6.35%, 10.43%, and 10.24% [2]. Group 2: Operational Performance - Weikang Pharmaceutical has experienced a continuous decline in performance since its IPO, with net profits dropping from 108 million yuan in 2020 to a loss of 147 million yuan in 2024 [3]. - The company's revenue in the first quarter of 2025 fell by 65.10% year-on-year to 69.77 million yuan, with losses expanding to 9.85 million yuan [3]. - The gross margin decreased significantly from 72.41% in 2020 to 42.23% in 2024, reflecting a 30 percentage point drop over five years [3]. Group 3: Strategic Changes - In response to ongoing challenges, Weikang Pharmaceutical divested its retail pharmaceutical business in September 2024 to focus on traditional Chinese medicine research and health products [4]. - Despite the recognition of its flagship product, Yinhuang Diban, as the top cold medicine in retail for 2024, the company has not been able to reverse its declining performance [4]. Group 4: Investor Rights and Compensation - Following the administrative penalties, investors who purchased Weikang Pharmaceutical shares between March 31, 2021, and December 27, 2024, may claim compensation for losses incurred [5]. - As of June 2025, Weikang Pharmaceutical's stock price was 17.04 yuan, with a market capitalization of 2.47 billion yuan, reflecting a significant decline in investor confidence [5].

Core Viewpoint - Zhejiang Weikang Pharmaceutical Co., Ltd. has been fined 16 million yuan for years of financial fraud and disclosure violations, revealing a systemic chain of illegal activities by its actual controller Liu Zhongliang [1] Group 1: Financial Misconduct - From 2020 to June 2023, Liu Zhongliang misappropriated company funds through fictitious engineering payments, with the total amount rising from 78.11 million yuan to 151 million yuan, peaking at 10.43% of net assets [2] - Of the misappropriated funds, 56.29 million yuan was used to repay personal loans, while 85.39 million yuan was directly occupied, leading to long-term inflation of company assets and concealment of receivables [2] Group 2: Misrepresentation in Bond Issuance - In December 2022, Weikang Pharmaceutical falsely claimed in its prospectus for a 680 million yuan convertible bond that there was no fund misappropriation by the actual controller, despite the undisclosed amount reaching 147 million yuan at that time [3] - The issuance of the convertible bond was ultimately terminated in February 2024 [3] Group 3: Regulatory Actions and Governance Issues - Liu Zhongliang received a total fine of 7 million yuan for his dual roles as actual controller and direct responsible person, while the company was fined 5 million yuan and five senior executives were fined a total of 4 million yuan [3] - Despite Liu Zhongliang stepping down as chairman in May 2024, he retained control of the company through a 36.82% shareholding, indicating a lack of effective governance mechanisms in the family-run business [3]

Core Viewpoint - Weikang Pharmaceutical faces administrative penalties from the Zhejiang Securities Regulatory Bureau for information disclosure violations, including non-disclosure of related party non-operating fund occupation and inaccuracies in convertible bond prospectus [1][2][5] Group 1: Administrative Penalties - The Zhejiang Securities Regulatory Bureau plans to impose a total fine exceeding 14 million yuan on Weikang Pharmaceutical and its responsible individuals, including a 5 million yuan fine on the company and a 7 million yuan fine on its actual controller Liu Zhongliang [1][5] - Liu Zhongliang, who served as the chairman from March 2015 until May 2024, has retired and is no longer involved in the company [1][2] Group 2: Fund Misappropriation - Liu Zhongliang directed Weikang Pharmaceutical to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal account, constituting non-operating fund occupation [2][3] - From 2018 to 2020, Liu Zhongliang borrowed 56.29 million yuan from the company to support a friend's new drug development, which was used for various personal and business expenses [2][3] Group 3: Financial Performance - Weikang Pharmaceutical's net profit has declined since its IPO in 2020, with losses reported in 2023 and the first quarter of 2025, showing a significant drop in revenue and profitability [6][7] - The company's gross margin has decreased from 72.41% in 2020 to 50.39% in 2023, attributed to a decline in high-margin prescription drug sales and increased costs [7] Group 4: Future Outlook - Liu Zhongliang expressed optimism about the company's future, focusing on the development and production of traditional Chinese medicine products, believing that difficulties are temporary and new growth will emerge in two to three years [7]